Degrons in cancer

Science Signaling

Volumn 10, Issue 470, 2017, Pages

  Mészáros, Bálint ^a   Kumar, Manjeet ^b   Gibson, Toby J ^b   Uyar, Bora ^c   Dosztányi, Zsuzsanna ^d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BETA TRCP PROTEIN; CBL PROTEIN; CYCLIN D1; DEGRON; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LIGASE; PROTEASOME; PROTEIN P53; PROTEIN TYROSINE KINASE; RTK PROTEIN; SCF E3 LIGASE; TRANSCRIPTION FACTOR NRF2; TUMOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN; ATP DEPENDENT 26S PROTEASE; ONCOPROTEIN; UBIQUITIN PROTEIN LIGASE;

CARCINOGENESIS; CELL CYCLE; DRUG DESIGN; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE DISRUPTION; GENE FUSION; GENE MUTATION; HUMAN; LETHALITY; MALIGNANT NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; UBIQUITINATION; UPREGULATION; WNT SIGNALING PATHWAY; BINDING SITE; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR MODEL; NEOPLASM; PROTEIN DOMAIN;

BINDING SITES; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; ONCOGENE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DOMAINS; PROTEOLYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 85016240764     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aak9982     Document Type: Review

References (360)

1. A. M. Goh, C. R. Coffill, D. P. Lane, The role of mutant p53 in human cancer. J. Pathol. 223, 116-126 (2011).
2. P. A. J. Muller, K. H. Vousden, p53 mutations in cancer. Nat. Cell Biol. 15, 2-8 (2013).
3. D. P. Lane, p53, guardian of the genome. Nature 358, 15-16 (1992).
4. N. A. Laurie, S. L. Donovan, C.-S. Shih, J. Zhang, N. Mills, C. Fuller, A. Teunisse, S. Lam, Y. Ramos, A. Mohan, D. Johnson, M. Wilson, C. Rodriguez-Galindo, M. Quarto, S. Francoz, S. M. Mendrysa, R. K. Guy, J.-C. Marine, A. G. Jochemsen, M. A. Dyer, Inactivation of the p53 pathway in retinoblastoma. Nature 444, 61-66 (2006).
5. D. J. Gordon, B. Resio, D. Pellman, Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189-203 (2012).
6. R. A. Veitia, M. C. Potier, Gene dosage imbalances: Action, reaction, and models. Trends Biochem. Sci. 40, 309-317 (2015).
7. B. G. Wilson, C. W. M. Roberts, SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011).
8. E. Provost, A. McCabe, J. Stern, I. Lizardi, T. G. D'Aquila, D. L. Rimm, Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 24, 2667-2676 (2005).
9. B. Uyar, R. J. Weatheritt, H. Dinkel, N. E. Davey, T. J. Gibson, Proteome-wide analysis of human disease mutations in short linear motifs: Neglected players in cancer? Mol. Biosyst. 10, 2626-2642 (2014).
10. A. Ciechanover, Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 12, 1178-1190 (2005).
11. I. Livneh, V. Cohen-Kaplan, C. Cohen-Rosenzweig, N. Avni, A. Ciechanover, The life cycle of the 26S proteasome: From birth, through regulation and function, and onto its death. Cell Res. 26, 869-885 (2016).
12. D. Voges, P. Zwickl, W. Baumeister, The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068 (1999).
13. N. Li, Y. Zhang, X. Han, K. Liang, J. Wang, L. Feng, W. Wang, Z. Songyang, C. Lin, L. Yang, Y. Yu, J. Chen, Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev. 29, 157-170 (2015).
14. M. Miteva, K. Keusekotten, K. Hofmann, G. J. K. Praefcke, R. J. Dohmen, Sumoylation as a signal for polyubiquitylation and proteasomal degradation. Subcell. Biochem. 54, 195-214 (2010).
15. S. Bhattacharyya, H. Yu, C. Mim, A. Matouschek, Regulated protein turnover: Snapshots of the proteasome in action. Nat. Rev. Mol. Cell Biol. 15, 122-133 (2014).
16. J. S. Thrower, L. Hoffman, M. Rechsteiner, C. M. Pickart, Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102 (2000).
17. A. Hershko, A. Ciechanover, The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61, 761-807 (1992).
18. W. Li, M. H. Bengtson, A. Ulbrich, A. Matsuda, V. A. Reddy, A. Orth, S. K. Chanda, S. Batalov, C. A. P. Joazeiro, Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLOS ONE 3, e1487 (2008).
19. R. J. Deshaies, C. A. P. Joazeiro, RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434 (2009).
20. D. Rotin, S. Kumar, Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 10, 398-409 (2009).
21. M. D. Petroski, R. J. Deshaies, Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9-20 (2005).
22. L. Pintard, A. Willems, M. Peter, Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J. 23, 1681-1687 (2004).
23. S. Jackson, Y. Xiong, CRL4s: The CUL4-RING E3 ubiquitin ligases. Trends Biochem. Sci. 34, 562-570 (2009).
24. T. Cardozo, M. Pagano, The SCF ubiquitin ligase: Insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739-751 (2004).
25. F. Okumura, A. Joo-Okumura, K. Nakatsukasa, T. Kamura, The role of cullin 5-containing ubiquitin ligases. Cell Div. 11, 1 (2016).
26. W. Ponyeam, T. Hagen, Characterization of the Cullin7 E3 ubiquitin ligase-Heterodimerization of cullin substrate receptors as a novel mechanism to regulate cullin E3 ligase activity. Cell. Signal. 24, 290-295 (2012).
27. K. I. Nakayama, K. Nakayama, Ubiquitin ligases: Cell-cycle control and cancer. Nat. Rev. Cancer 6, 369-381 (2006).
28. L. Aravind, E. V. Koonin, The U box is a modified RING finger-A common domain in ubiquitination. Curr. Biol. 10, R132-R134 (2000).
29. S. Hatakeyama, M. Yada, M. Matsumoto, N. Ishida, K.-I. Nakayama, U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111-33120 (2001).
30. H. Tao, B. N. Simmons, S. Singireddy, M. Jakkidi, K. M. Short, T. C. Cox, M. A. Massiah, Structure of the MID1 tandem B-boxes reveals an interaction reminiscent of intermolecular ring heterodimers. Biochemistry 47, 2450-2457 (2008).
31. B. Eisenhaber, N. Chumak, F. Eisenhaber, M.-T. Hauser, The ring between ring fingers (RBR) protein family. Genome Biol. 8, 209 (2007).
32. A. M. Weissman, Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2, 169-178 (2001).
33. R. Suryadinata, S. N. A. Roesley, G. Yang, B. Sarčević, Mechanisms of generating polyubiquitin chains of different topology. Cells 3, 674-689 (2014).
34. D. Komander, M. Rape, The ubiquitin code. Annu. Rev. Biochem. 81, 203-229 (2012).
35. L. Jin, A. Williamson, S. Banerjee, I. Philipp, M. Rape, Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell 133, 653-665 (2008).
36. B. M. Jehn, I. Dittert, S. Beyer, K. von der Mark, W. Bielke, c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. J. Biol. Chem. 277, 8033-8040 (2002).
37. D. Mukhopadhyay, H. Riezman, Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315, 201-205 (2007).
38. L. Sun, Z. J. Chen, The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16, 119-126 (2004).
39. C. M. Pickart, D. Fushman, Polyubiquitin chains: Polymeric protein signals. Curr. Opin. Chem. Biol. 8, 610-616 (2004).
40. L. Hicke, R. Dunn, Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19, 141-172 (2003).
41. J. Spence, S. Sadis, A. L. Haas, D. Finley, A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15, 1265-1273 (1995).
42. J. Spence, R. R. Gali, G. Dittmar, F. Sherman, M. Karin, D. Finley, Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 102, 67-76 (2000).
43. L. Deng, C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, C. Pickart, Z. J. Chen, Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361 (2000).
44. K. Rajalingam, I. Dikic, Expanding the ubiquitin code. Cell 164, 1074-1074.e1 (2016).
45. M. Hochstrasser, Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30, 405-439 (1996).
46. K. Van Roey, B. Uyar, R. J. Weatheritt, H. Dinkel, M. Seiler, A. Budd, T. J. Gibson, N. E. Davey, Short linear motifs: Ubiquitous and functionally diverse protein interaction modules directing cell regulation. Chem. Rev. 114, 6733-6778 (2014).
47. N. E. Davey, D. O. Morgan, Building a regulatory network with short linear sequence motifs: Lessons from the degrons of the anaphase-promoting complex. Mol. Cell 64, 12-23 (2016).
48. H. Dinkel, K. V. Roey, S. Michael, M. Kumar, B. Uyar, B. Altenberg, V. Milchevskaya, M. Schneider, H. Kühn, A. Behrendt, S. L. Dahl, V. Damerell, S. Diebel, S. Kalman, S. Klein, A. C. Knudsen, C. Mäder, S. Merrill, A. Staudt, V. Thiel, L. Welti, N. E. Davey, F. Diella, T. J. Gibson, ELM 2016-Data update and new functionality of the eukaryotic linear motif resource. Nucleic Acids Res. 44, D294-D300 (2016).
49. M. Wade, Y. V. Wang, G. M. Wahl, The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20, 299-309 (2010).
50. P. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, N. P. Pavletich, Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
51. A. C. Carrano, E. Eytan, A. Hershko, M. Pagano, SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193-199 (1999).
52. Skp2 ubiquitin ligase. Mol. Cell 20, 9-19 (2005).
53. A. W. Lau, H. Fukushima, W. Wei, The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front. Biosci.. 17, 2197-2212 (2012).
54. β-TrCP1 ubiquitin ligase. Mol. Cell 11, 1445-1456 (2003).
55. M. Welcker, B. E. Clurman, FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93 (2008).
56. B. Mohapatra, G. Ahmad, S. Nadeau, N. Zutshi, W. An, S. Scheffe, L. Dong, D. Feng, B. Goetz, P. Arya, T. A. Bailey, N. Palermo, G. E. O. Borgstahl, A. Natarajan, S. M. Raja, M. Naramura, V. Band, H. Band, Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochim. Biophys. Acta 1833, 122-139 (2013).
57. W.-C. Hon, M. I. Wilson, K. Harlos, T. D. W. Claridge, C. J. Schofield, C. W. Pugh, P. H. Maxwell, P. J. Ratcliffe, D. I. Stuart, E. Y. Jones, Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975-978 (2002).
58. L. Gossage, T. Eisen, E. R. Maher, VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55-64 (2015).
59. T. Hunter, The age of crosstalk: Phosphorylation, ubiquitination, and beyond. Mol. Cell 28, 730-738 (2007).
60. Y. Yang, M. T. Bedford, Titivated for destruction: The methyl degron. Mol. Cell 48, 487-488 (2012).
61. J. An, S. Ren, S. J. Murphy, S. Dalangood, C. Chang, X. Pang, Y. Cui, L. Wang, Y. Pan, X. Zhang, Y. Zhu, C. Wang, G. C. Halling, L. Cheng, W. R. Sukov, R. J. Karnes, G. Vasmatzis, Q. Zhang, J. Zhang, J. C. Cheville, J. Yan, Y. Sun, H. Huang, Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904-916 (2015).
62. W. Gan, X. Dai, A. Lunardi, Z. Li, H. Inuzuka, P. Liu, S. Varmeh, J. Zhang, L. Cheng, Y. Sun, J. M. Asara, A. H. Beck, J. Huang, P. P. Pandolfi, W. Wei, SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917-930 (2015).
63. S.-C. Lo, X. Li, M. T. Henzl, L. J. Beamer, M. Hannink, Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 25, 3605-3617 (2006).
64. M. McMahon, N. Thomas, K. Itoh, M. Yamamoto, J. D. Hayes, Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: A two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281, 24756-24768 (2006).
65. M. Welcker, E. A. Larimore, J. Swanger, M. T. Bengoechea-Alonso, J. E. Grim, J. Ericsson, N. Zheng, B. E. Clurman, Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev. 27, 2531-2536 (2013).
66. M. Welcker, B. E. Clurman, Oncoprotein ubiquitylation: Dimers, degrons, and degradation. Cell Cycle 13, 1829-1830 (2014).
67. A. Gonnissen, S. Isebaert, K. Haustermans, Targeting the Hedgehog signaling pathway in cancer: Beyond smoothened. Oncotarget 6, 13899-13913 (2015).
68. L. L. Rubin, F. J. de Sauvage, Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5, 1026-1033 (2006).
69. Q. Zhang, Q. Shi, Y. Chen, T. Yue, S. Li, B. Wang, J. Jiang, Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 106, 21191-21196 (2009).
70. E. G. Huntzicker, I. S. Estay, H. Zhen, L. A. Lokteva, P. K. Jackson, A. E. Oro, Dual degradation signals control Gli protein stability and tumor formation. Genes Dev. 20, 276-281 (2006).
71. L. Di Marcotullio, A. Greco, D. Mazzà, G. Canettieri, L. Pietrosanti, P. Infante, S. Coni, M. Moretti, E. De Smaele, E. Ferretti, I. Screpanti, A. Gulino, Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal. Oncogene 30, 65-76 (2011).
72. L. Di Marcotullio, E. Ferretti, A. Greco, E. De Smaele, A. Po, M. A. Sico, M. Alimandi, G. Giannini, M. Maroder, I. Screpanti, A. Gulino, Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat. Cell Biol. 8, 1415-1423 (2006).
73. K. Van Roey, H. Dinkel, R. J. Weatheritt, T. J. Gibson, N. E. Davey, The switches. ELM resource: A compendium of conditional regulatory interaction interfaces. Sci. Signal. 6, rs7 (2013).
74. K. Sakaguchi, S. Saito, Y. Higashimoto, S. Roy, C. W. Anderson, E. Appella, Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275, 9278-9283 (2000).
75. C. Liu, Y. Li, M. Semenov, C. Han, G.-H. Baeg, Y. Tan, Z. Zhang, X. Lin, X. He, Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847 (2002).
76. Q. Sun, R. A. Jackson, C. Ng, G. R. Guy, J. Sivaraman, Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain. PLOS ONE 5, e12819 (2010).
77. Y. Liu, J. Lau, W. Li, W. Tempel, L. Li, A. Dong, A. Narula, S. Qin, J. Min, Structural basis for the regulatory role of the PPxY motifs in the thioredoxin-interacting protein TXNIP. Biochem. J. 473, 179-187 (2016).
78. W. Wei, J. Jin, S. Schlisio, J. W. Harper, W. G. Kaelin Jr., The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33 (2005).
79. B. Gao, S.-M. Lee, D. Fang, The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells. J. Biol. Chem. 281, 29711-29718 (2006).
80. I. Cunha-Ferreira, I. Bento, A. Pimenta-Marques, S. C. Jana, M. Lince-Faria, P. Duarte, J. Borrego-Pinto, S. Gilberto, T. Amado, D. Brito, A. Rodrigues-Martins, J. Debski, N. Dzhindzhev, M. Bettencourt-Dias, Regulation of autophosphorylation controls PLK4 self-destruction and centriole number. Curr. Biol. 23, 2245-2254 (2013).
81. A. J. Holland, W. Lan, S. Niessen, H. Hoover, D. W. Cleveland, Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J. Cell Biol. 188, 191-198 (2010).
82. Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 20, 47-64 (2006).
83. R. J. Weatheritt, N. E. Davey, T. J. Gibson, Linear motifs confer functional diversity onto splice variants. Nucleic Acids Res. 40, 7123-7131 (2012).
84. M. A. Maynard, H. Qi, J. Chung, E. H. L. Lee, Y. Kondo, S. Hara, R. C. Conaway, J. W. Conaway, M. Ohh, Multiple splice variants of the human HIF-3α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278, 11032-11040 (2003).
85. P. de Bie, A. Ciechanover, Ubiquitination of E3 ligases: Self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ. 18, 1393-1402 (2011).
86. A. Jamal, M. Swarnalatha, S. Sultana, P. Joshi, S. K. Panda, V. Kumar, The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2. Cell Cycle 14, 2688-2700 (2015).
87. W. Wei, N. G. Ayad, Y. Wan, G.-J. Zhang, M. W. Kirschner, W. G. Kaelin Jr., Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194-198 (2004).
88. M. Fuxreiter, P. Tompa, I. Simon, Local structural disorder imparts plasticity on linear motifs. Bioinformatics 23, 950-956 (2007).
89. B. Mészáros, Z. Dosztányi, I. Simon, Disordered binding regions and linear motifs-Bridging the gap between two models of molecular recognition. PLOS ONE 7, e46829 (2012).
90. M. Gao, T. Labuda, Y. Xia, E. Gallagher, D. Fang, Y.-C. Liu, M. Karin, Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306, 271-275 (2004).
91. W. Wei, W. G. Kaelin Jr., Good COP1 or bad COP1? In vivo veritas. J. Clin. Invest. 121, 1263-1265 (2011).
92. M. Eldeeb, R. Fahlman, The-N-end rule: The beginning determines the end. Protein Pept. Lett. 23, 343-348 (2016).
93. M. Guharoy, P. Bhowmick, M. Sallam, P. Tompa, Tripartite degrons confer diversity and specificity on regulated protein degradation in the ubiquitin-proteasome system. Nat. Commun. 7, 10239 (2016).
94. B. Alberts, A. Johnson, J. Lewis, D. Morgan, M. Raff, K. Roberts, P. Walter, Molecular Biology of the Cell (Garland Science, ed. 6, 2014).
95. K. I. Nakayama, K. Nakayama, Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 16, 323-333 (2005).
96. R. Wäsch, D. Engelbert, Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24, 1-10 (2005).
97. C. M. Cummings, C. A. Bentley, S. A. Perdue, P. W. Baas, J. D. Singer, The Cul3/Klhdc5 E3 ligase regulates p60/katanin and is required for normal mitosis in mammalian cells. J. Biol. Chem. 284, 11663-11675 (2009).
98. C. Lindon, J. Pines, Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J. Cell Biol. 164, 233-241 (2004).
99. T. J. McGarry, M. W. Kirschner, Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93, 1043-1053 (1998).
100. P. Clute, J. Pines, Temporal and spatial control of cyclin B1 destruction in metaphase. Nat. Cell Biol. 1, 82-87 (1999).
101. A. Zur, M. Brandels, Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J. 20, 792-801 (2001).
102. W. Qi, H. Yu, KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the anaphase-promoting complex/cyclosome. J. Biol. Chem. 282, 3672-3679 (2007).
103. B. Di Fiore, N. E. Davey, A. Hagting, D. Izawa, J. Mansfeld, T. J. Gibson, J. Pines, The ABBA motif binds APC/C activators and is shared by APC/C substrates and regulators. Dev. Cell 32, 358-372 (2015).
104. A. Yamanaka, S. Hatakeyama, K.-. Kominami, M. Kitagawa, M. Matsumoto, K.-. Nakayama, Cell cycle-dependent expression of mammalian E2-C regulated by the anaphase-promoting complex/cyclosome. Mol. Biol. Cell 11, 2821-2831 (2000).
105. B. O. Petersen, C. Wagener, F. Marinoni, E. R. Kramer, M. Melixetian, E. L. Denchi, C. Gieffers, C. Matteucci, J.-M. Peters, K. Helin, Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev. 14, 2330-2343 (2000).
106. J. A. Robbins, F. R. Cross, Regulated degradation of the APC coactivator Cdc20. Cell Div. 5, 23 (2010).
107. R. S. Hames, S. L. Wattam, H. Yamano, R. Bacchieri, A. M. Fry, APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. EMBO J. 20, 7117-7127 (2001).
108. L. E. Littlepage, J. V. Ruderman, Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev. 16, 2274-2285 (2002).
109. M. V. Hadjihannas, D. B. Bernkopf, M. Brückner, J. Behrens, Cell cycle control of Wnt/β-catenin signalling by conductin/axin2 through CDC20. EMBO Rep. 13, 347-354 (2012).
110. N. von der Lehr, S. Johansson, S. Wu, F. Bahram, A. Castell, C. Cetinkaya, P. Hydbring, I. Weidung, K. Nakayama, K. I. Nakayama, O. Söderberg, T. K. Kerppola, L.-G. Larsson, The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 11, 1189-1200 (2003).
111. G. Bornstein, J. Bloom, D. Sitry-Shevah, K. Nakayama, M. Pagano, A. Hershko, Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278, 25752-25757 (2003).
112. Kip1, polyploidy and centrosome overduplication. EMBO J. 19, 2069-2081 (2000).
113. T. Kamura, T. Hara, S. Kotoshiba, M. Yada, N. Ishida, H. Imaki, S. Hatakeyama, K. Nakayama, K. I. Nakayama, Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl. Acad. Sci. U.S.A. 100, 10231-10236 (2003).
114. J. A. Diehl, F. Zindy, C. J. Sherr, Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972 (1997).
115. J. Méndez, X. H. Zou-Yang, S.-Y. Kim, M. Hidaka, W. P. Tansey, B. Stillman, Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol. Cell 9, 481-491 (2002).
116. Skp2 ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J. Biol. Chem. 278, 30854-30858 (2003).
117. A. Marti, C. Wirbelauer, M. Scheffner, W. Krek, Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat. Cell Biol. 1, 14-19 (1999).
118. Skp2. Genes Dev. 16, 2946-2957 (2002).
119. A. Seki, J. A. Coppinger, H. Du, C.-Y. Jang, J. R. Yates, G. Fang, Plk1- and β-TrCP-dependent degradation of Bora controls mitotic progression. J. Cell Biol. 181, 65-78 (2008).
120. βTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell 4, 813-826 (2003).
121. N. Watanabe, H. Arai, Y. Nishihara, M. Taniguchi, N. Watanabe, T. Hunter, H. Osada, M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc. Natl. Acad. Sci. U.S.A. 101, 4419-4424 (2004).
122. Y. Kanemori, K. Uto, N. Sagata, β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl. Acad. Sci. U.S.A. 102, 6279-6284 (2005).
123. D. Olmeda, S. Castel, S. Vilaró, A. Cano, β-Catenin regulation during the cell cycle: Implications in G2/M and apoptosis. Mol. Biol. Cell 14, 2844-2860 (2003).
124. L. Busino, M. Donzelli, M. Chiesa, D. Guardavaccaro, D. Ganoth, N. V. Dorrello, A. Hershko, M. Pagano, G. F. Draetta, Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 426, 87-91 (2003).
125. G. C. Rogers, N. M. Rusan, D. M. Roberts, M. Peifer, S. L. Rogers, The SCF Slimb ubiquitin ligase regulates Plk4/Sak levels to block centriole reduplication. J. Cell Biol. 184, 225-239 (2009).
126. C. L. Frank, X. Ge, Z. Xie, Y. Zhou, L.-H. Tsai, Control of activating transcription factor 4 (ATF4) persistence by multisite phosphorylation impacts cell cycle progression and neurogenesis. J. Biol. Chem. 285, 33324-33337 (2010).
127. S. D'Annibale, J. Kim, R. Magliozzi, T. Yew Low, S. Mohammed, A. J. R. Heck, D. Guardavaccaro, Proteasome-dependent degradation of transcription factor activating enhancer-binding protein 4 (TFAP4) controls mitotic division. J. Biol. Chem. 289, 7730-7737 (2014).
128. K. T. Bieging, S. S. Mello, L. D. Attardi, Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359-370 (2014).
129. K. H. Vousden, K. M. Ryan, p53 and metabolism. Nat. Rev. Cancer 9, 691-700 (2009).
130. Y. Liu, Y. He, A. Jin, A. P. Tikunov, L. Zhou, L. A. Tollini, P. Leslie, T.-H. Kim, L. O. Li, R. A. Coleman, Z. Gu, Y. Q. Chen, J. M. Macdonald, L. M. Graves, Y. Zhang, Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation. Proc. Natl. Acad. Sci. U.S.A. 111, E2414-E2422 (2014).
131. Z. T. Gu, H. Wang, L. Li, Y. S. Liu, X. B. Deng, S. F. Huo, F. F. Yuan, Z. F. Liu, H. S. Tong, L. Su, Heat stress induces apoptosis through transcription-independent p53-mediated mitochondrial pathways in human umbilical vein endothelial cell. Sci. Rep. 4, 4469 (2014).
132. A. J. Giaccia, M. B. Kastan, The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
133. J. S. Fridman, S. W. Lowe, Control of apoptosis by p53. Oncogene 22, 9030-9040 (2003).
134. M. Oren, Decision making by p53: Life, death and cancer. Cell Death Differ. 10, 431-442 (2003).
135. J. Pflaum, S. Schlosser, M. Müller, p53 family and cellular stress responses in cancer. Front. Oncol. 4, 285 (2014).
136. M. H. Kubbutat, K. H. Vousden, Keeping an old friend under control: Regulation of p53 stability. Mol. Med. Today 4, 250-256 (1998).
137. C. C.-K. Chao, Mechanisms of p53 degradation. Clin. Chim. Acta 438, 139-147 (2015).
138. M.-. Halaby, R. Hakem, A. Hakem, Pirh2: An E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation. Cell Cycle 12, 2733-2737 (2013).
139. L. Sun, L. Shi, F. Wang, P. Huangyang, W. Si, J. Yang, Z. Yao, Y. Shang, Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization. J. Biol. Chem. 286, 4226-4235 (2011).
140. N. T. Nihira, K. Ogura, K. Shimizu, B. J. North, J. Zhang, D. Gao, H. Inuzuka, W. Wei, Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci. Signal. 10, eaai8026 (2017).
141. H. H. Choi, C. Gully, C.-H. Su, G. Velazquez-Torres, P.-C. Chou, C. Tseng, R. Zhao, L. Phan, T. Shaiken, J. Chen, S. C. Yeung, M.-H. Lee, COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ. Oncogene 30, 4791-4801 (2011).
142. D. Dornan, I. Wertz, H. Shimizu, D. Arnott, G. D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, V. M. Dixit, The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92 (2004).
143. C. L. Brooks, W. Gu, p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315 (2006).
144. R. P. Leng, Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, S. Benchimol, Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003).
145. M. Li, C. L. Brooks, N. Kon, W. Gu, A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879-886 (2004).
146. J. M. Cummins, B. Vogelstein, HAUSP is required for p53 destabilization. Cell Cycle 3, 689-692 (2004).
147. V. Marcel, P. Hainaut, p53 isoforms-A conspiracy to kidnap p53 tumor suppressor activity? Cell. Mol. Life Sci. 66, 391-406 (2009).
148. C. Y. Logan, R. Nusse, The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004).
149. J. L. Stamos, W. I. Weis, The β-catenin destruction complex. Cold Spring Harb. Perspect. Biol. 5, a007898 (2013).
150. K. Willert, S. Shibamoto, R. Nusse, Wnt-induced dephosphorylation of axin releases β-catenin from the axin complex. Genes Dev. 13, 1768-1773 (1999).
151. Y. Zhang, S. Liu, C. Mickanin, Y. Feng, O. Charlat, G. A. Michaud, M. Schirle, X. Shi, M. Hild, A. Bauer, V. E. Myer, P. M. Finan, J. A. Porter, S.-M. A. Huang, F. Cong, RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat. Cell Biol. 13, 623-629 (2011).
152. N. Barker, H. Clevers, Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5, 997-1014 (2006).
153. Target genes of Wnt/beta-catenin signaling, http://web.stanford.edu/~rnusse/pathways/targets.html [accessed 26 February 2017].
154. M. A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
155. S. R. Hubbard, W. T. Miller, Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19, 117-123 (2007).
156. C. B. Thien, W. Y. Langdon, Cbl: Many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2, 294-307 (2001).
157. C. Ng, R. A. Jackson, J. P. Buschdorf, Q. Sun, G. R. Guy, J. Sivaraman, Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. EMBO J. 27, 804-816 (2008).
158. H. Dou, L. Buetow, A. Hock, G. J. Sibbet, K. H. Vousden, D. T. Huang, Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat. Struct. Mol. Biol. 19, 184-192 (2012).
159. L. Buetow, G. Tria, S. F. Ahmed, A. Hock, H. Dou, G. J. Sibbet, D. I. Svergun, D. T. Huang, Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation. BMC Biol. 14, 76 (2016).
160. G. Carpenter, The EGF receptor: A nexus for trafficking and signaling. BioEssays 22, 697-707 (2000).
161. H. Waterman, Y. Yarden, Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142-152 (2001).
162. K. Haglund, I. Dikic, The role of ubiquitylation in receptor endocytosis and endosomal sorting. J. Cell Sci. 125, 265-275 (2012).
163. Y. Mosesson, K. Shtiegman, M. Katz, Y. Zwang, G. Vereb, J. Szollosi, Y. Yarden, Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J. Biol. Chem. 278, 21323-21326 (2003).
164. K. Haglund, S. Sigismund, S. Polo, I. Szymkiewicz, P. P. Di Fiore, I. Dikic, Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 5, 461-466 (2003).
165. J. A. Cooper, T. Kaneko, S. S. C. Li, Cell regulation by phosphotyrosine-targeted ubiquitin ligases. Mol. Cell. Biol. 35, 1886-1897 (2015).
166. T. Ravid, J. M. Heidinger, P. Gee, E. M. Khan, T. Goldkorn, c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J. Biol. Chem. 279, 37153-37162 (2004).
167. J. Sun, M. Pedersen, S. Bengtsson, L. Rönnstrand, Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. Exp. Cell Res. 313, 3935-3942 (2007).
168. E. S. M. Wong, C. W. Fong, J. Lim, P. Yusoff, B. C. Low, W. Y. Langdon, G. R. Guy, Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J. 21, 4796-4808 (2002).
169. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., K. W. Kinzler, Cancer genome landscapes. Science 339, 1546-1558 (2013).
170. S. A. Forbes, COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777-D783 (2016).
171. H. Makishima, K. Yoshida, N. Nguyen, B. Przychodzen, M. Sanada, Y. Okuno, K. Peng Ng, K. O. Gudmundsson, B. A. Vishwakarma, A. Jerez, I. Gomez-Segui, M. Takahashi, Y. Shiraishi, Y. Nagata, K. Guinta, H. Mori, M. A. Sekeres, K. Chiba, H. Tanaka, H. Muramatsu, H. Sakaguchi, R. L. Paquette, M. A. McDevitt, S. Kojima, Y. Saunthararajah, S. Miyano, L.-Y. Shih, Y. Du, S. Ogawa, J. P. Maciejewski, Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942-946 (2013).
172. R. Piazza, S. Valletta, N. Winkelmann, S. Redaelli, R. Spinelli, A. Pirola, L. Antolini, L. Mologni, C. Donadoni, E. Papaemmanuil, S. Schnittger, D.-W. Kim, J. Boultwood, F. Rossi, G. Gaipa, G. P. De Martini, Paola F. di Celle, H. Gyung Jang, V. Fantin, G. R. Bignell, V. Magistroni, T. Haferlach, E. Maria Pogliani, P. J. Campbell, A. J. Chase, W. J. Tapper, P. Nicholas C Cross, C. Gambacorti-Passerini, Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat. Genet. 45, 18-24 (2013).
173. T. Nguyen, P. Nioi, C. B. Pickett, The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-13295 (2009).
174. L. M. Solis, C. Behrens, W. Dong, M. Suraokar, N. C. Ozburn, C. A. Moran, A. H. Corvalan, S. Biswal, S. G. Swisher, B. N. Bekele, J. D. Minna, D. J. Stewart, I. I. Wistuba, Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 16, 3743-3753 (2010).
175. T. Shibata, T. Ohta, K. I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, S. Hirohashi, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U.S.A. 105, 13568-13573 (2008).
176. S. J. Loughran, E. A. Kruse, D. F. Hacking, C. A. de Graaf, C. D. Hyland, T. A. Willson, K. J. Henley, S. Ellis, A. K. Voss, D. Metcalf, D. J. Hilton, W. S. Alexander, B. T. Kile, The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 9, 810-819 (2008).
177. B. Laxman, S. A. Tomlins, R. Mehra, D. S. Morris, L. Wang, B. E. Helgeson, R. B. Shah, M. A. Rubin, J. T. Wei, A. M. Chinnaiyan, Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8, 885-888 (2006).
178. K. Shimizu, H. Ichikawa, A. Tojo, Y. Kaneko, N. Maseki, Y. Hayashi, M. Ohira, S. Asano, M. Ohki, An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc. Natl. Acad. Sci. U.S.A. 90, 10280-10284 (1993).
179. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X.-W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin, A. M. Chinnaiyan, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
180. P. C. Hollenhorst, L. P. McIntosh, B. J. Graves, Genomic and biochemical insights into the specificity of ETS transcription factors. Annu. Rev. Biochem. 80, 437-471 (2011).
181. S. Oh, S. Shin, R. Janknecht, ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors. Biochim. Biophys. Acta 1826, 1-12 (2012).
182. A. C. Vitari, K. G. Leong, K. Newton, C. Yee, K. O'Rourke, J. Liu, L. Phu, R. Vij, R. Ferrando, S. S. Couto, S. Mohan, A. Pandita, J.-A. Hongo, D. Arnott, I. E. Wertz, W.-Q. Gao, D. M. French, V. M. Dixit, COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474, 403-406 (2011).
183. N. Agrawal, M. J. Frederick, C. R. Pickering, C. Bettegowda, K. Chang, R. J. Li, C. Fakhry, T.-X. Xie, J. Zhang, J. Wang, N. Zhang, A. K. El-Naggar, S. A. Jasser, J. N. Weinstein, L. Treviño, J. A. Drummond, D. M. Muzny, Y. Wu, L. D. Wood, R. H. Hruban, W. H. Westra, W. M. Koch, J. A. Califano, R. A. Gibbs, D. Sidransky, B. Vogelstein, V. E. Velculescu, N. Papadopoulos, D. A. Wheeler, K. W. Kinzler, J. N. Myers, Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
184. X. Yuan, M. Zhang, H. Wu, H. Xu, N. Han, Q. Chu, S. Yu, Y. Chen, K. Wu, Expression of Notch1 correlates with breast cancer progression and prognosis. PLOS ONE 10, e0131689 (2015).
185. P. Baliakas, A. Hadzidimitriou, L.-A. Sutton, D. Rossi, E. Minga, N. Villamor, M. Larrayoz, J. Kminkova, A. Agathangelidis, Z. Davis, E. Tausch, E. Stalika, B. Kantorova, L. Mansouri, L. Scarfò, D. Cortese, V. Navrkalova, M. J. J. Rose-Zerilli, K. E. Smedby, G. Juliusson, A. Anagnostopoulos, A. M. Makris, A. Navarro, J. Delgado, D. Oscier, C. Belessi, S. Stilgenbauer, P. Ghia, S. Pospisilova, G. Gaidano, E. Campo, J. C. Strefford, K. Stamatopoulos, R. Rosenquist; European Research Initiative on CLL (ERIC), Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29, 329-336 (2015).
186. R. Kridel, B. Meissner, S. Rogic, M. Boyle, A. Telenius, B. Woolcock, J. Gunawardana, C. Jenkins, C. Cochrane, S. Ben-Neriah, K. Tan, R. D. Morin, S. Opat, L. H. Sehn, J. M. Connors, M. A. Marra, A. P. Weng, C. Steidl, R. D. Gascoyne, Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119, 1963-1971 (2012).
187. J. Moretti, C. Brou, Ubiquitinations in the Notch signaling pathway. Int. J. Mol. Sci. 14, 6359-6381 (2013).
188. S. Rogers, R. Wells, M. Rechsteiner, Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 234, 364-368 (1986).
189. C. J. Fryer, J. B. White, K. A. Jones, Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol. Cell 16, 509-520 (2004).
190. R. J. Davis, M. Welcker, B. E. Clurman, Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. Cancer Cell 26, 455-464 (2014).
191. A. Malyukova, T. Dohda, N. von der Lehr, S. Akhondi, M. Corcoran, M. Heyman, C. Spruck, D. Grandér, U. Lendahl, O. Sangfelt, The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67, 5611-5616 (2007).
192. J. O'Neil, J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J. P. Meijerink, R. Pieters, G. Draetta, R. Sears, B. E. Clurman, A. T. Look, FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
193. M. Blattner, D. J. Lee, C. O'Reilly, K. Park, T. Y. MacDonald, F. Khani, K. R. Turner, Y.-L. Chiu, P. J. Wild, I. Dolgalev, A. Heguy, A. Sboner, S. Ramazangolu, H. Hieronymus, C. Sawyers, A. K. Tewari, H. Moch, G. Suk Yoon, Y. Chul Known, O. Andrén, K. Fall, F. Demichelis, J. M. Mosquera, B. D. Robinson, C. E. Barbieri, M. A. Rubin, SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16, 14-20 (2014).
194. C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J.-P. Theurillat, T. A. White, P. Stojanov, E. Van Allen, N. Stransky, E. Nickerson, S.-S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin, L. A. Garraway, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
195. C. Geng, K. Rajapakshe, S. S. Shah, J. Shou, V. K. Eedunuri, C. Foley, W. Fiskus, M. Rajendran, S. A. Chew, M. Zimmermann, R. Bond, B. He, C. Coarfa, N. Mitsiades, Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 74, 5631-5643 (2014).
196. S. C. Kales, P. E. Ryan, M. M. Nau, S. Lipkowitz, Cbl and human myeloid neoplasms: The Cbl oncogene comes of age. Cancer Res. 70, 4789-4794 (2010).
197. Y.-H. C. Tan, S. Krishnaswamy, S. Nandi, R. Kanteti, S. Vora, K. Onel, R. Hasina, F.-Y. Lo, E. El-Hashani, G. Cervantes, M. Robinson, S. C. Kales, S. Lipkowitz, T. Karrison, M. Sattler, E. E. Vokes, Y.-C. Wang, R. Salgia, CBL is frequently altered in lung cancers: Its relationship to mutations in MET and EGFR tyrosine kinases. PLOS ONE 5, e8972 (2010).
198. M. Lerner, M. Corcoran, D. Cepeda, M. L. Nielsen, R. Zubarev, F. Pontén, M. Uhlén, S. Hober, D. Grandér, O. Sangfelt, The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD. Mol. Biol. Cell 18, 1670-1682 (2007).
199. B. Kapanadze V. Kashuba, A. Baranova, O. Rasool, W. van Everdink, Y. Liu, A. Syomov, M. Corcoran, A. Poltaraus, V. Brodyansky, N. Syomova, A. Kazakov, R. Ibbotson, A. van den Berg, R. Gizatullin, L. Fedorova, G. Sulimova, A. Zelenin, L. Deaven, H. Lehrach, D. Grander, C. Buys, D. Oscier, E. R. Zabarovsky, S. Einhorn, N. Yankovsky, A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Lett. 426, 266-270 (1998).
200. W. He, D. C. Dorn, H. Erdjument-Bromage, P. Tempst, M. A. S. Moore, J. Massagué, Hematopoiesis controlled by distinct TIF1γ and Smad4 branches of the TGFβ pathway. Cell 125, 929-941 (2006).
201. R. M. Pommier, J. Gout, D. F. Vincent, L. B. Alcaraz, N. Chuvin, V. Arfi, S. Martel, B. Kaniewski, G. Devailly, G. Fourel, P. Bernard, C. Moyret-Lalle, S. Ansieau, A. Puisieux, U. Valcourt, S. Sentis, L. Bartholin, TIF1γ suppresses tumor progression by regulating mitotic checkpoints and chromosomal stability. Cancer Res. 75, 4335-4350 (2015).
202. R. Aucagne, N. Droin, J. Paggetti, B. Lagrange, A. Largeot, A. Hammann, A. Bataille, L. Martin, K.-P. Yan, P. Fenaux, R. Losson, E. Solary, J.-N. Bastie, L. Delva, Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J. Clin. Invest. 121, 2361-2370 (2011).
203. Z.-Y. Ding, G. N. Jin, W. Wang, W. X. Chen, Y. H. Wu, X. Ai, L. Chen, W. G. Zhang, H. F. Liang, A. Laurence, M. Z. Zhang, P. K. Datta, B. Zhang, X. P. Chen, Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology 60, 1620-1636 (2014).
204. N. S. Latysheva, M. E. Oates, L. Maddox, T. Flock, J. Gough, M. Buljan, R. J. Weatheritt, M. M. Babu, Molecular principles of gene fusion mediated rewiring of protein interaction networks in cancer. Mol. Cell 63, 579-592 (2016).
205. G. L. Bond, K. M. Hirshfield, T. Kirchhoff, G. Alexe, E. E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, W. Hait, D. Toppmeyer, K. Offit, A. J. Levine, MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 66, 5104-5110 (2006).
206. G. L. Bond, W. Hu, E. E. Bond, H. Robins, S. G. Lutzker, N. C. Arva, J. Bargonetti, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S.-J. Hwang, L. C. Strong, G. Lozano, A. J. Levine, A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004).
207. J. Momand, D. Jung, S. Wilczynski, J. Niland, The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459 (1998).
208. S. Araki, J. A. Eitel, C. N. Batuello, K. Bijangi-Vishehsaraei, X.-J. Xie, D. Danielpour, K. E. Pollok, D. A. Boothman, L. D. Mayo, TGF-β1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J. Clin. Invest. 120, 290-302 (2010).
209. E. Rayburn, R. Zhang, J. He, H. Wang, MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5, 27-41 (2005).
210. G. Reifenberger, L. Liu, K. Ichimura, E. E. Schmidt, V. P. Collins, Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53, 2736-2739 (1993).
211. Y. K. Satija, A. Bhardwaj, S. Das, A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Int. J. Cancer 133, 2759-2768 (2013).
212. K. Kitagawa, Y. Kotake, M. Kitagawa, Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 100, 1374-1381 (2009).
213. M. Shimada, K. Kitagawa, Y. Dobashi, T. Isobe, T. Hattori, C. Uchida, K. Abe, Y. Kotake, T. Oda, H. Suzuki, K. Hashimoto, M. Kitagawa, High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci. 100, 866-872 (2009).
214. D. Frescas, M. Pagano, Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: Tipping the scales of cancer. Nat. Rev. Cancer 8, 438-449 (2008).
215. C. Mosimann, G. Hausmann, K. Basler, β-Catenin hits chromatin: Regulation of Wnt target gene activation. Nat. Rev. Mol. Cell Biol. 10, 276-286 (2009).
216. S. Munemitsu, I. Albert, B. Rubinfeld, P. Polakis, Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell. Biol. 16, 4088-4094 (1996).
217. A. Kobayashi, M.-I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, M. Yamamoto, Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24, 7130-7139 (2004).
218. K. M. Mulvaney, J. P. Matson, P. F. Siesser, T. Y. Tamir II, D. Goldfarb, T. M. Jacobs, E. W. Cloer, J. S. Harrison, C. Vaziri, J. G. Cook, M. B. Major, Identification and characterization of MCM3 as a Kelch-like ECH-associated protein 1 (KEAP1) substrate. J. Biol. Chem. 291, 23719-23733 (2016).
219. J. D. Hayes, M. McMahon, NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34, 176-188 (2009).
220. L. A. Muscarella, P. Parrella, V. D'Alessandro, A. la Torre, R. Barbano, A. Fontana, A. Tancredi, V. Guarnieri, T. Balsamo, M. Coco, M. Copetti, F. Pellegrini, P. De Bonis, M. Bisceglia, G. Scaramuzzi, E. Maiello, V. M. Valori, G. Merla, G. Vendemiale, V. M. Fazio, Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 6, 710-719 (2011).
221. A. Singh, V. Misra, R. K. Thimmulappa, H. Lee, S. Ames, M. O. Hoque, J. G. Herman, S. B. Baylin, D. Sidransky, E. Gabrielson, M. V. Brock, S. Biswal, Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLOS Med. 3, e420 (2006).
222. B. E. Hast, E. W. Cloer, D. Goldfarb, H. Li, P. F. Siesser, F. Yan, V. Walter, N. Zheng, D. Neil Hayes, M. B. Major, Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res. 74, 808-817 (2014).
223. FBX4-αB crystallin complex. Mol. Cell 24, 355-366 (2006).
224. H. Okabe, S.-H. Lee, J. Phuchareon, D. G. Albertson, F. McCormick, O. Tetsu, A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLOS ONE 1, e128 (2006).
225. 288. Biochem. J. 457, 43-56 (2014).
226. L. P. Vaites, E. K. Lee, Z. Lian, O. Barbash, D. Roy, M. Wasik, A. J. P. Klein-Szanto, A. K. Rustgi, J. Alan Diehl, The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol. Cell. Biol. 31, 4513-4523 (2011).
227. M. K. Santra, N. Wajapeyee, M. R. Green, F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459, 722-725 (2009).
228. R. Agami, R. Bernards, Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102, 55-66 (2000).
229. O. Barbash, J. A. Diehl, SCF(Fbx4/αB-crystallin) E3 ligase: When one is not enough. Cell Cycle 7, 2983-2986 (2008).
230. G. Moreno-Bueno, S. Rodríguez-Perales, C. Sánchez-Estévez, D. Hardisson, D. Sarrió, J. Prat, J. C. Cigudosa, X. Matias-Guiu, J. Palacios, Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22, 6115-6118 (2003).
231. Y. Ikeda, K. Oda, O. Hiraike-Wada, T. Koso, A. Miyasaka, T. Kashiyama, M. Tanikawa, K. Sone, K. Nagasaka, D. Maeda, K. Kawana, S. Nakagawa, M. Fukayama, O. Tetsu, T. Fujii, T. Yano, S. Kozuma, Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer. Oncol. Rep. 30, 584-588 (2013).
232. Fbx4 ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14, 68-78 (2008).
233. B. B. Chen, J. R. Glasser, T. A. Coon, R. K. Mallampalli, F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene 31, 2566-2579 (2012).
234. M. A. Velasco-Velázquez, Z. Li, M. Casimiro, E. Loro, N. Homsi, R. G. Pestell, Examining the role of cyclin D1 in breast cancer. Future Oncol. 7, 753-765 (2011).
235. K. Bani-Hani, I. G. Martin, L. J. Hardie, N. Mapstone, J. A. Briggs, D. Forman, C. P. Wild, Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J. Natl. Cancer Inst. 92, 1316-1321 (2000).
236. R. Schmitz, R. M. Young, M. Ceribelli, S. Jhavar, W. Xiao, M. Zhang, G. Wright, A. L. Shaffer, D. J. Hodson, E. Buras, X. Liu, J. Powell, Y. Yang, W. Xu, H. Zhao, H. Kohlhammer, A. Rosenwald, P. Kluin, H. K. Müller-Hermelink, G. Ott, R. D. Gascoyne, J. M. Connors, L. M. Rimsza, E. Campo, E. S. Jaffe, J. Delabie, E. B. Smeland, M. D. Ogwang, S. J. Reynolds, R. I. Fisher, R. M. Braziel, R. R. Tubbs, J. R. Cook, D. D. Weisenburger, W. C. Chan, S. Pittaluga, W. Wilson, T. A. Waldmann, M. Rowe, S. M. Mbulaiteye, A. B. Rickinson, L. M. Staudt, Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
237. P. Peschard, M. Park, Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3, 519-523 (2003).
238. P. Peschard, T. M. Fournier, L. Lamorte, M. A. Naujokas, H. Band, W. Y. Langdon, M. Park, Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (2001).
239. A. Drilon, MET exon 14 alterations in lung cancer: Exon skipping extends half-life. Clin. Cancer Res. 22, 2832-2834 (2016).
240. R. S. Heist, H. S. Shim, S. Gingipally, M. Mino-Kenudson, L. Le, J. F. Gainor, Z. Zheng, M. Aryee, J. Xia, P. Jia, H. Jin, Z. Zhao, W. Pao, J. A. Engelman, A. J. Iafrate, MET exon 14 skipping in non-small cell lung cancer. Oncologist 21, 481-486 (2016).
241. N. R. Soman, P. Correa, B. A. Ruiz, G. N. Wogan, The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. U.S.A. 88, 4892-4896 (1991).
242. J. Yu, S. Miehlke, M. P. Ebert, J. Hoffmann, M. Breidert, B. Alpen, T. Starzynska, M. Stolte Prof, P. Malfertheiner, E. Bayerdörffer, Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 88, 1801-1806 (2000).
243. P. M. Chan, S. Ilangumaran, J. La Rose, A. Chakrabartty, R. Rottapel, Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell. Biol. 23, 3067-3078 (2003).
244. P. S. Lee, Y. Wang, M. G. Dominguez, Y. G. Yeung, M. A. Murphy, D. D. Bowtell, E. R. Stanley, The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 18, 3616-3628 (1999).
245. S. A. Ridge, M. Worwood, D. Oscier, A. Jacobs, R. A. Padua, FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl. Acad. Sci. U.S.A. 87, 1377-1380 (1990).
246. L. Frederick, X.-Y. Wang, G. Eley, C. D. James, Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60, 1383-1387 (2000).
247. J. Erikson, A. Ar-Rushdi, H. L. Drwinga, P. C. Nowell, C. M. Croce, Transcriptional activation of the translocated c-myc oncogene in Burkitt lymphoma. Proc. Natl. Acad. Sci. U.S.A. 80, 820-824 (1983).
248. L. M. Boxer, C. V. Dang, Translocations involving c-myc and c-myc function. Oncogene 20, 5595-5610 (2001).
249. L. R. Thomas, W. P. Tansey, Proteolytic control of the oncoprotein transcription factor Myc. Adv. Cancer Res. 110, 77-106 (2011).
250. M. Welcker, A. Orian, J. Jin, J. A. Grim, J. W. Harper, R. N. Eisenman, B. E. Clurman, The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc. Natl. Acad. Sci. U.S.A. 101, 9085-9090 (2004).
251. C. V. Dang, MYC on the path to cancer. Cell 149, 22-35 (2012).
252. Y. Luan, P. Wang, FBW7-mediated ubiquitination and degradation of KLF5. World J. Biol. Chem. 5, 216-223 (2014).
253. A. B. Bialkowska, Y. Liu, M. O. Nandan, V. W. Yang, A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α). J. Biol. Chem. 289, 5997-6005 (2014).
254. J.-H. Mao, J. Perez-losada, D. Wu, R. DelRosario, R. Tsunematsu, K. I. Nakayama, K. Brown, S. Bryson, A. Balmain, Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432, 775-779 (2004).
255. B. Hao, S. Oehlmann, M. E. Sowa, J. W. Harper, N. P. Pavletich, Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131-143 (2007).
256. S. Akhoondi, D. Sun, N. von der Lehr, S. Apostolidou, K. Klotz, A. Maljukova, D. Cepeda, H. Fiegl, D. Dofou, C. Marth, E. Mueller-Holzner, M. Corcoran, M. Dagnell, S. Z. Nejad, B. Noori Nayer, M. R. Zali, J. Hansson, S. Egyhazi, F. Petersson, P. Sangfelt, H. Nordgren, D. Grander, S. I. Reed, M. Widschwendter, O. Sangfelt, C. Spruck, FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007).
257. J.-K. Oh, E. Weiderpass, Infection and cancer: Global distribution and burden of diseases. Ann. Glob. Health 80, 384-392 (2014).
258. A. Calistri, D. Munegato, I. Carli, C. Parolin, G. Palù, The ubiquitin-conjugating system: Multiple roles in viral replication and infection. Cells 3, 386-417 (2014).
259. M. K. White, J. S. Pagano, K. Khalili, Viruses and human cancers: A long road of discovery of molecular paradigms. Clin. Microbiol. Rev. 27, 463-481 (2014).
260. W. Greene, W. Zhang, M. He, C. Witt, F. Ye, S.-J. Gao, The ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells. PLOS Pathog. 8, e1002703 (2012).
261. F. Sarkari, T. Sanchez-Alcaraz, S. Wang, M. N. Holowaty, Y. Sheng, L. Frappier, EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLOS Pathog. 5, e1000624 (2009).
262. J.-M. Peloponese Jr., H. Iha, Venkat R. K. Yedavalli, A. Miyazato, Y. Li, K. Haller, M. Benkirane, K.-T. Jeang, Ubiquitination of human T-cell leukemia virus type 1 tax modulates its activity. J. Virol. 78, 11686-11695 (2004).
263. M. Scheffner, B. A. Werness, J. M. Huibregtse, A. J. Levine, P. M. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
264. S. Beaudenon, J. M. Huibregtse, HPV E6, E6AP and cervical cancer. BMC Biochem. 9 (suppl. 1), S4 (2008).
265. M. N. Holowaty, L. Frappier, HAUSP/USP7 as an Epstein-Barr virus target. Biochem. Soc. Trans. 32, 731-732 (2004).
266. K. Huh, X. Zhou, H. Hayakawa, J.-Y. Cho, T. A. Libermann, J. Jin, J. Wade Harper, K. Munger, Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81, 9737-9747 (2007).
267. M.-Y. Cha, C.-M. Kim, Y.-M. Park, W.-S. Ryu, Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 39, 1683-1693 (2004).
268. M. Fujimuro, S. D. Hayward, The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3β. J. Virol. 77, 8019-8030 (2003).
269. M. R. Higgs, H. Lerat, J.-M. Pawlotsky, Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene 32, 4683-4693 (2013).
270. R. Houben, C. Adam, A. Baeurle, S. Hesbacher, J. Grimm, S. Angermeyer, K. Henzel, S. Hauser, R. Elling, E. B. Bröcker, S. Gaubatz, J. C. Becker, D. Schrama, An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int. J. Cancer 130, 847-856 (2012).
271. Fbw7. Cell Host Microbe 14, 125-135 (2013).
272. B. Zhang, A. Srirangam, D. A. Potter, A. Roman, HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 24, 2585-2588 (2005).
273. J. M. Boname, P. J. Lehner, What has the study of the K3 and K5 viral ubiquitin E3 ligases taught us about ubiquitin-mediated receptor regulation? Viruses 3, 118-131 (2011).
274. R. Kumar, C. B. Whitehurst, J. S. Pagano, The Rad6/18 ubiquitin complex interacts with the Epstein-Barr virus deubiquitinating enzyme, BPLF1, and contributes to virus infectivity. J. Virol. 88, 6411-6422 (2014).
275. A. R. Fehr, D. Yu, Control the host cell cycle: Viral regulation of the anaphase-promoting complex. J. Virol. 87, 8818-8825 (2013).
276. H. zur Hausen, H. Schulte-Holthausen, G. Klein, W. Henle, G. Henle, P. Clifford, L. Santesson, EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058 (1970).
277. T. H. Rabbitts, A. Forster, P. Hamlyn, R. Baer, Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma. Nature 309, 592-597 (1984).
278. M. Yada, S. Hatakeyama, T. Kamura, M. Nishiyama, R. Tsunematsu, H. Imaki, N. Ishida, F. Okumura, K. Nakayama, K. I. Nakayama, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23, 2116-2125 (2004).
279. HOS/β-TrCP E3 ubiquitin ligase regulates extent of NF-κB activation. J. Biol. Chem. 278, 48942-48949 (2003).
280. S. M. Shafiee A. Seghatoleslam, M. Nikseresht, S. Vahid Hosseini, M. Alizadeh-Naeeni, A. Safaei, A. Akbar Owji, UBE2Q1 expression in human colorectal tumors and cell lines. Mol. Biol. Rep. 40, 7045-7051 (2013).
281. W. Y. Kim, W. G. Kaelin, Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
282. J. K. Maranchie, J. R. Vasselli, J. Riss, J. S. Bonifacino, W. M. Linehan, R. D. Klausner, The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002).
283. H. A. J. Alwan, E. J. J. van Zoelen, J. E. M. van Leeuwen, Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J. Biol. Chem. 278, 35781-35790 (2003).
284. H. Davis, I. Tomlinson, CDC4/FBXW7 and the 'just enough' model of tumourigenesis. J. Pathol. 227, 131-135 (2012).
285. A. H. Berger, A. G. Knudson, P. P. Pandolfi, A continuum model for tumour suppression. Nature 476, 163-169 (2011).
286. T.-C. Lee, D. W. Threadgill, Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis 47, 85-92 (2009).
287. M. H. Lee, H. Y. Yang, Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell. Mol. Life Sci. 58, 1907-1922 (2001).
288. Kip2 down-regulation in oncogenesis of bladder carcinoma: An immunohistochemical study. Tumori 94, 556-562 (2008).
289. V. A. Arboleda, H. Lee, R. Parnaik, A. Fleming, A. Banerjee, B. Ferraz-de-Souza, E. C. Délot, I. A. Rodriguez-Fernandez, D. Braslavsky, I. Bergadá, E. C. Dell'Angelica, S. F. Nelson, J. A. Martinez-Agosto, J. C. Achermann, E. Vilain, Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat. Genet. 44, 788-792 (2012).
290. J.-C. Marine, Spotlight on the role of COP1 in tumorigenesis. Nat. Rev. Cancer 12, 455-464 (2012).
291. J. Lee, P. Zhou, DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol. Cell 26, 775-780 (2007).
292. L. Wang, G. He, P. Zhang, X. Wang, M. Jiang, L. Yu., Interplay between MDM2, MDMX, Pirh2 and COP1: The negative regulators of p53. Mol. Biol. Rep. 38, 229-236 (2011).
293. D. Dornan, H. Shimizu, A Mah, T. Dudhela, M. Eby, K. O'rourke, S. Seshagiri, V. M. Dixit, ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 313, 1122-1126 (2006).
294. D. Dornan, S. Bheddah, K. Newton, W. Ince, G. D. Frantz, P. Dowd, H. Koeppen, V. M. Dixit, D. M. French, COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64, 7226-7230 (2004).
295. D. Migliorini, S. Bogaerts, D. Defever, R. Vyas, G. Denecker, E. Radaelli, A. Zwolinska, V. Depaepe, T. Hochepied, W. C. Skarnes, J.-C. Marine, Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J. Clin. Invest. 121, 1329-1343 (2011).
296. F. Wu, X. Dai, W. Gan, L. Wan, M. Li, N. Mitsiades, W. Wei, Q. Ding, Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett. 385, 207-214 (2017).
297. G. Li, W. Ci, S. Karmakar, K. Chen, R. Dhar, Z. Fan, Z. Guo, J. Zhang, Y. Ke, L. Wang, M. Zhuang, S. Hu, X. Li, L. Zhou, X. Li, M. F. Calabrese, E. R. Watson, S. M. Prasad, C. Rinker-Schaeffer, S. E. Eggener, T. Stricker, Y. Tian, B. A. Schulman, J. Liu, K. P. White, SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25, 455-468 (2014).
298. C. Nathan, Specificity of a third kind: Reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 111, 769-778 (2003).
299. M. Kobayashi, L. Li, N. Iwamoto, Y. Nakajima-Takagi, H. Kaneko, Y. Nakayama, M. Eguchi, Y. Wada, Y. Kumagai, M. Yamamoto, The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol. Cell. Biol. 29, 493-502 (2009).
300. D. A. Abed, M. Goldstein, H. Albanyan, H. Jin, L. Hu, Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm. Sin. B. 5, 285-299 (2015).
301. N. J. Yoo, H. R. Kim, Y. R. Kim, C. H. An, S. H. Lee, Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60, 943-952 (2012).
302. A. Singh, S. Boldin-Adamsky, R. K. Thimmulappa, S. K. Rath, H. Ashush, J. Coulter, A. Blackford, S. N. Goodman, F. Bunz, W. H. Watson, E. Gabrielson, E. Feinstein, S. Biswal, RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68, 7975-7984 (2008).
303. S. Cialfi, R. Palermo, S. Manca, C. De Blasio, P. Vargas Romero, S. Checquolo, D. Bellavia, D. Uccelletti, M. Saliola, A. D'Alessandro, L. Zolla, A. Gulino, I. Screpanti, C. Talora, Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis. Cell Cycle 13, 2046-2055 (2014).
304. J. Thélu, P. Rossio, B. Favier, Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol. 2, 7 (2002).
305. M. Nicolas, A. Wolfer, K. Raj, J. A. Kummer, P. Mill, M. van Noort, C.-. Hui, H. Clevers, G. Paolo Dotto, F. Radtke, Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416-421 (2003).
306. N. J. Wang, Z. Sanborn, K. L. Arnett, L. J. Bayston, W. Liao, C. M. Proby, I. M. Leigh, E. A. Collisson, P. B. Gordon, L. Jakkula, S. Pennypacker, Y. Zou, M. Sharma, J. P. North, S. S. Vemula, T. M. Mauro, I. M. Neuhaus, P. E. Leboit, J. S. Hur, K. Park, N. Huh, P. Y. Kwok, S. T. Arron, P. P. Massion, A. E. Bale, D. Haussler, J. E. Cleaver, J. W. Gray, P. T. Spellman, A. P. South, J. C. Aster, S. C. Blacklow, R. J. Cho, Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 108, 17761-17766 (2011).
307. V. Sriuranpong, M. W. Borges, R. K. Ravi, D. R. Arnold, B. D. Nelkin, S. B. Baylin, D. W. Ball, Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 61, 3200-3205 (2001).
308. Y. Yang, B. G. Goldstein, H.-H. Chao, J. P. Katz, KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol. Ther. 4, 1216-1221 (2005).
309. K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
310. F. Zammarchi, M. Morelli, M. Menicagli, C. Di Cristofano, K. Zavaglia, A. Paolucci, D. Campani, P. Aretini, U. Boggi, F. Mosca, A. Cavazzana, L. Cartegni, G. Bevilacqua, C. Maria Mazzanti, KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am. J. Pathol. 178, 361-372 (2011).
311. Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 68, 4631-4639 (2008).
312. H. S. Yoon, V. W. Yang, Requirement of Krüppel-like factor 4 in preventing entry into mitosis following DNA damage. J. Biol. Chem. 279, 5035-5041 (2004).
313. D. Wei, M. Kanai, S. Huang, K. Xie, Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 27, 23-31 (2006).
314. A. M. Ghaleb, M. O. Nandan, S. Chanchevalap, W. B. Dalton, I. M. Hisamuddin, V. W. Yang, Krüppel-like factors 4 and 5: The yin and yang regulators of cellular proliferation. Cell Res. 15, 92-96 (2005).
315. W. Hu, W. L. Hofstetter, H. Li, Y. Zhou, Y. He, A. Pataer, L. Wang, K. Xie, S. G. Swisher, B. Fang, Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin. Cancer Res. 15, 5688-5695 (2009).
316. H. Guan, L. Xie, F. Leithäuser, L. Flossbach, P. Möller, T. Wirth, A. Ushmorov, KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 116, 1469-1478 (2010).
317. B. D. Rowland, R. Bernards, D. S. Peeper, The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7, 1074-1082 (2005).
318. A. M. Ghaleb, J. P. Katz, K. H. Kaestner, J. X. Du, V. W. Yang, Krüppel-like factor 4 exhibits antiapoptotic activity following γ-radiation-induced DNA damage. Oncogene 26, 2365-2373 (2007).
319. K. W. Foster, A. R. Frost, P. McKie-Bell, C. Y. Lin, J. A. Engler, W. E. Grizzle, J. M. Ruppert, Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res. 60, 6488-6495 (2000).
320. M.-P. Tetreault, Y. Yang, J. P. Katz, Krüppel-like factors in cancer. Nat. Rev. Cancer 13, 701-713 (2013).
321. A. M. Gamper, X. Qiao, J. Kim, L. Zhang, M. C. DeSimone, W. Kimryn Rathmell, Y. Wan, Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Mol. Cell 45, 233-243 (2012).
322. J. R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M. H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F.-M. Duh, I. Lubensky, D. R. Duan, C. Florence, R. Pozzatti, M. M. Walther, N. H. Bander, H. B. Grossman, H. Brauch, S. Pomer, J. D. Brooks, W. B. Isaacs, M. I. Lerman, B. Zbar, W. M. Linehan, Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994).
323. K. R. Ong, E. R. Woodward, P. Killick, C. Lim, F. Macdonald, E. R. Maher, Genotype-phenotype correlations in von Hippel-Lindau disease. Hum. Mutat. 28, 143-149 (2007).
324. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
325. J. Xie, H. Kim, L. A. Moreau, S. Puhalla, J. Garber, M. Al Abo, S. Takeda, A. D. D'Andrea, RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J. Clin. Invest. 125, 1523-1532 (2015).
326. J. J. Thomas, M. Abed, J. Heuberger, R. Novak, Y. Zohar, A. P. Beltran Lopez, J. S. Trausch-Azar, M. X. G. Ilagan, D. Benhamou, G. Dittmar, R. Kopan, W. Birchmeier, A. L. Schwartz, A. Orian, RNF4-dependent oncogene activation by protein stabilization. Cell Rep. 16, 3388-3400 (2016).
327. M. Diefenbacher, A. Orian, Stabilization of nuclear oncoproteins by RNF4 and the ubiquitin system in cancer. Mol. Cell. Oncol. 4, e1260671 (2017).
328. S. M. Molineaux, Molecular pathways: Targeting proteasomal protein degradation in cancer. Clin. Cancer Res. 18, 15-20 (2012).
329. D. Chen, M. Frezza, S. Schmitt, J. Kanwar, Q. P. Dou, Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr. Cancer Drug Targets 11, 239-253 (2011).
330. V. Landré, B. Rotblat, S. Melino, F. Bernassola, G. Melino, Screening for E3-ubiquitin ligase inhibitors: Challenges and opportunities. Oncotarget 5, 7988-8013 (2014).
331. F. C. Streich Jr., C. D. Lima, Structural and functional insights to ubiquitin-like protein conjugation. Annu. Rev. Biophys. 43, 357-379 (2014).
332. T. A. Soucy, P. G. Smith, M. A. Milhollen, A. J. Berger, J. M. Gavin, S. Adhikari, J. E. Brownell, K. E. Burke, D. P. Cardin, S. Critchley, C. A. Cullis, A. Doucette, J. J. Garnsey, J. L. Gaulin, R. E. Gershman, A. R. Lublinsky, A. McDonald, H. Mizutani, U. Narayanan, E. J. Olhava, S. Peluso, M. Rezaei, M. D. Sintchak, T. Talreja, M. P. Thomas, T. Traore, S. Vyskocil, G. S. Weatherhead, J. Yu, J. Zhang, L. R. Dick, C. F. Claiborne, M. Rolfe, J. B. Bolen, S. P. Langston, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
333. X. Huang, V. M. Dixit, Drugging the undruggables: Exploring the ubiquitin system for drug development. Cell Res. 26, 484-498 (2016).
334. C. Corbi-Verge, P. M. Kim, Motif mediated protein-protein interactions as drug targets. Cell Commun. Signal 14, 8 (2016).
335. L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. A. Liu, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
336. K. H. Khoo, K. K. Hoe, C. S. Verma, D. P. Lane, Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236 (2014).
337. Y. Cheng, T. LeGall, C. J. Oldfield, J. P. Mueller, Y.-Y. J. Van, P. Romero, M. S. Cortese, V. N. Uversky, A. K. Dunker, Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24, 435-442 (2006).
338. V. V. Iyer, A review of stapled peptides and small molecules to inhibit protein-protein interactions in cancer. Curr. Med. Chem. 23, 3025-3043 (2016).
339. Y. S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K. H. To, K. A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. Elkin, Z. Filipovic, F. Z. Qureshi, H. Cai, P. Berry, E. Feyfant, X. E. Shi, J. Horstick, D. A. Annis, A. M. Manning, N. Fotouhi, H. Nash, L. T. Vassilev, T. K. Sawyer, Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 110, E3445-E3454 (2013).
340. M. Wade, Y.-C. Li, G. M. Wahl, MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96 (2013).
341. A. Burgess, K. M. Chia, S. Haupt, D. Thomas, Y. Haupt, E. Lim, Clinical overview of MDM2/X-targeted therapies. Front. Oncol. 6, 7 (2016).
342. A. Bellomaria, G. Barbato, G. Melino, M. Paci, S. Melino, Recognition mechanism of p63 by the E3 ligase Itch: Novel strategy in the study and inhibition of this interaction. Cell Cycle 11, 3638-3648 (2012).
343. T. Mund, M. J. Lewis, S. Maslen, H. R. Pelham, Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proc. Natl. Acad. Sci. U.S.A. 111, 16736-16741 (2014).
344. U. Kossatz, N. Dietrich, L. Zender, J. Buer, M. P. Manns, N. P. Malek, Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602-2607 (2004).
345. J. R. Skaar, J. K. Pagan, M. Pagano, SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 13, 889-903 (2014).
346. K. M. Sakamoto, K. B. Kim, A. Kumagai, F. Mercurio, C. M. Crews, R. J. Deshaies, Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U.S.A. 98, 8554-8559 (2001).
347. K. R. Chi, Drug developers delve into the cell's trash-disposal machinery. Nat. Rev. Drug Discov. 15, 295-297 (2016).
348. M. Toure, C. M. Crews, Small-molecule PROTACS: New approaches to protein degradation. Angew. Chem. Int. Ed. Engl. 55, 1966-1973 (2016).
349. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, J. Zeddis, B. Barlogie, Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999).
350. S. Tseng, G. Pak, K. Washenik, M. K. Pomeranz, J. L. Shupack, Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 35, 969-979 (1996).
351. CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 5, e354 (2015).
352. CRBN ubiquitin ligase. Nature 532, 127-130 (2016).
353. CRBN ubiquitin ligase. Nature 535, 252-257 (2016).
354. M. D. Hartmann, I. Boichenko, M. Coles, F. Zanini, A. N. Lupas, B. Hernandez Alvarez, Thalidomide mimics uridine binding to an aromatic cage in cereblon. J. Struct. Biol. 188, 225-232 (2014).
355. X. Tan, L. I. A. Calderon-Villalobos, M. Sharon, C. Zheng, C. V. Robinson, M. Estelle, N. Zheng, Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-645 (2007).
356. P. Tal, S. Eizenberger, E. Cohen, N. Goldfinger, S. Pietrokovski, M. Oren, V. Rotter, Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget 7, 11817-11837 (2016).
357. X. Lu, A. Pearson, J. Lunec, The MYCN oncoprotein as a drug development target. Cancer Lett. 197, 125-130 (2003).
358. M. W. Richards, S. G. Burgess, E. Poon, A. Carstensen, M. Eilers, L. Chesler, R. Bayliss, Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 113, 13726-13731 (2016).
359. B. C. Lechtenberg, A. Rajput, R. Sanishvili, M. K. Dobaczewska, C. F. Ware, P. D. Mace, S. J. Riedl, Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation. Nature 529, 546-550 (2016).
360. H. Wickham, ggplot2: Elegant Graphics for Data Analysis (Springer, 2016).